Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs- Netherlands

doi 10.1007/s10637-020-00907-4

Full Text

Abstract

Available in

Categories

Date

February 4, 2020

Authors

Sarit Assouline

Anne-Marie Young

Publisher

Springer Science and Business Media LLC

Related search

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology

Cancer Research

English

A New Peptide Vaccine OCV-501: In Vitro Pharmacology and Phase 1 Study in Patients With Acute Myeloid Leukemia

Cancer Immunology, Immunotherapy

Cancer Research

English

AML1 (Acute Myeloid Leukemia 1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Cancer Research

English

Challenges in Treating Older Patients With Acute Myeloid Leukemia

Journal of Oncology

English

Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the BCL-2 Inhibitor Venetoclax in P53 Wild-Type Acute Myeloid Leukemia Models

Journal of Hematology and Oncology

Cancer Research

Molecular Biology

English

The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study

English

A Randomised Phase II Study of Interleukin-1 Receptor Antagonist in Acute Stroke Patients

Journal of Neurology, Neurosurgery and Psychiatry

English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma

Cancer Research

English

How I Treat Older Patients With Acute Myeloid Leukemia

Cancer Research

English